AstraZeneca Plans $1.5 Billion Manufacturing Facility In Singapore

Pharmaceutical giant AstraZeneca has announced its plans to construct a new $1.5 billion manufacturing facility in Singapore. The aim of this facility is to enhance the company’s global production of cancer-killing treatments. This move comes as part of AstraZeneca’s ongoing efforts to increase its manufacturing capabilities and meet the growing demand for its life-saving medications. The construction of the facility is expected to begin in 2022 and will help ensure a steady supply of cancer treatments to patients worldwide.
Pharmaceutical company AstraZeneca announced on Monday that it will be building its first-ever end-to-end production site for antibody drug conjugates. This new facility will handle all aspects of the manufacturing process at a commercial scale and is expected to be fully operational by 2029.
Pharmaceutical giant AstraZeneca has announced plans to construct a cutting-edge manufacturing facility in Singapore, focusing on the production of antibody drug conjugates (ADCs) used in cancer treatments. The company’s CEO, Pascal Soriot, highlighted the potential of ADCs to replace traditional chemotherapy and expressed confidence in Singapore’s reputation for complex manufacturing.